Table 1. Prognostic value of TSA-deregulated genes in primary MMC of newly diagnosed patients.
Probe set | Name | Adjusted P-value (Benjamini–Hochberg multiple testing correction) | Hazard ratio |
---|---|---|---|
Bad prognostic genes | |||
204563_at | SELL | 0.04 | 1.94 |
203567_s_at | TRIM38 | 0.04 | 1.96 |
201012_at | ANXA1 | 0.02 | 2.01 |
205352_at | SERPINI1 | 0.04 | 2.03 |
204944_at | PTPRG | 0.01 | 2.12 |
222651_s_at | TRPS1 | 0.03 | 2.17 |
214875_x_at | APLP2 | 0.01 | 2.19 |
203854_at | IF | 0.03 | 2.34 |
209958_s_at | PTHB1 | 0.01 | 2.35 |
209969_s_at | STAT1 | 0.009 | 2.37 |
205552_s_at | OAS1 | 0.01 | 2.50 |
226269_at | GDAP1 | 0.008 | 2.69 |
210432_s_at | SCN3A | 0.007 | 2.71 |
224701_at | PARP14 | 0.01 | 2.94 |
214079_at | DHRS2 | 4.76e−05 | 3.11 |
226158_at |
KLHL24 |
0.01 |
3.44 |
Good prognostic genes | |||
34408_at | RTN2 | 2.42e−05 | 0.28 |
225842_at | — | 9.96e−05 | 0.32 |
208894_at | HLA-DRA | 0.01 | 0.36 |
212464_s_at | FN1 | 0.01 | 0.37 |
202391_at | BASP1 | 7.01e−05 | 0.37 |
228726_at | SERPINB1 | 0.009 | 0.38 |
235301_at | KIAA1324L | 0.01 | 0.39 |
206385_s_at | ANK3 | 0.007 | 0.40 |
230233_at | RASGEF1B | 0.04 | 0.42 |
215193_x_at | HLA-DRB1 | 0.01 | 0.43 |
212636_at | QKI | 0.02 | 0.44 |
212998_x_at | HLA-DQB1 | 0.01 | 0.47 |
223218_s_at | NFKBIZ | 0.03 | 0.47 |
209198_s_at | SYT11 | 0.03 | 0.48 |
211990_at | HLA-DPA1 | 0.02 | 0.49 |
218918_at | MAN1C1 | 0.04 | 0.49 |
215388_s_at | CFH | 0.04 | 0.52 |
228152_s_at | FLJ31033 | 0.03 | 0.53 |
216834_at | RGS1 | 0.04 | 0.54 |
203695_s_at | DFNA5 | 0.04 | 0.54 |
219833_s_at | EFHC1 | 0.04 | 0.55 |
Abbreviations: TSA=trichostatin A; MMC=multiple myeloma cell.